Translational research in neurology and neuroscience 2010: Multiple sclerosis

Archives of Neurology

Volumn 67, Issue 11, 2010, Pages 1307-1315

  Stüve, Olaf ^a,b   Kieseier, Bernd C ^e   Hemmer, Bernhard ^f   Hartung, Hans Peter ^e   Awad, Amer ⁱ   Frohman, Elliot M ^b   Greenberg, Benjamin M ^b   Racke, Michael K ^j   Zamvil, Scott S ^k   Phillips, J Theodore ^d   Gold, Ralf ^g   Chan, Andrew ^g   Zettl, Uwe ^h   Milo, Ron ^c,l   Marder, Ellen ^a   Khan, Omar ^m   Eagar, Todd N ^b,c,l  

^a VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d Multiple Sclerosis Center at Texas Neurology   (United States)

^e HEINRICH HEINE UNIVERSITY   (Germany)

^f TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^g RUHR UNIVERSITY BOCHUM   (Germany)

^h UNIVERSITY OF ROSTOCK   (Germany)

ⁱ CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^k UNIVERSITY OF CALIFORNIA   (United States)

^l BARZILAI MEDICAL CENTER   (Israel)

^m WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; BETA1A INTERFERON; DACLIZUMAB; FLECAINIDE ACETATE; GLATIRAMER; LAMOTRIGINE; MITOXANTRONE; NATALIZUMAB; PHENYTOIN; PLACEBO; RILUZOLE;

ALLERGIC ENCEPHALOMYELITIS; CLINICAL EVALUATION; CLINICAL FEATURE; CLINICAL PRACTICE; CLINICAL TRIAL; DEGENERATIVE DISEASE; DISEASE ACTIVITY; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; EXPERIMENTAL STUDY; FEASIBILITY STUDY; FOOD AND DRUG ADMINISTRATION; HUMAN; MEDICAL PERSONNEL; MEDICAL RESEARCH; MONOTHERAPY; MULTIPLE SCLEROSIS; MYELITIS; NEUROIMAGING; NEUROLOGY; NEUROPROTECTION; NEUROSCIENCE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NEURITIS; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; PATIENT SAFETY; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PUPILLOMETRY; REVIEW; SCIENTIST; SUBSTITUTION THERAPY; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VISUAL SYSTEM;

ANIMALS; ANTIBODIES, MONOCLONAL; DISEASE MODELS, ANIMAL; DRUG DISCOVERY; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HUMANS; MULTIPLE SCLEROSIS; PEPTIDES; TRANSLATIONAL RESEARCH;

EID: 77957949997     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2010.158     Document Type: Review

References (135)

1. Rivers TM, Sprunt DH, Berry GP. Observations on attempts to produce acute disseminated encephalomyelitis. J Exp Med. 1933;58(1):39-53.
2. Rivers TM, Schwentker FF. Encephalomyelitis accompanied by myelin destruction experimentally produced in monkeys. J Exp Med. 1935;61(5):689-702.
3. Zamvil SS, Steinman L. The T lymphocyte in experimental allergic encephalomyelitis. Annu Rev Immunol. 1990;8:579-621.
4. Sriram S, Steiner I. Experimental allergic encephalomyelitis: a misleading model of multiple sclerosis. Ann Neurol. 2005;58(6):939-945.
5. Farrar JD, Smith JD, Murphy TL, Leung S, Stark GR, Murphy KM. Selective loss of type I interferon-induced STAT4 activation caused by a minisatellite insertion in mouse Stat2. Nat Immunol. 2000;1(1):65-69.
6. Arnon R. The development of Cop 1 (Copaxone), an innovative drug for the treatment of multiple sclerosis: personal reflections. Immunol Lett. 1996;50(1-2):1-15.
7. Teitelbaum D, Arnon R, Sela M. Copolymer 1: from basic research to clinical application. Cell Mol Life Sci. 1997;53(1):24-28.
8. Teitelbaum D, Meshorer A, Hirshfeld T, Arnon R, Sela M. Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide. Eur J Immunol. 1971;1(4):242-248.
9. Teitelbaum D, Webb C, Meshorer A, Arnon R, Sela M. Protection against experimental allergic encephalomyelitis. Nature. 1972;240(5383):564-566.
10. Teitelbaum D, Webb C, Meshorer A, Arnon R, Sela M. Suppression by several synthetic polypeptides of experimental allergic encephalomyelitis induced in guinea pigs and rabbits with bovine and human basic encephalitogen. Eur J Immunol. 1973;3(5):273-279.
11. McDevitt HO, Sela M. Genetic control of the antibody response, I: demonstration of determinant-specific differences in response to synthetic polypeptide antigens in two strains of inbred mice. J Exp Med. 1965;122(3):517-531.
12. Haines JL, Ter Minassian M, Bazyk A, et al; The Multiple Sclerosis Genetics Group. A complete genomic screen for multiple sclerosis underscores a role for the major histocompatibility complex. Nat Genet. 1996;13(4):469-471.
13. Ebers GC, Kukay K, Bulman DE, et al. A full genome search in multiple sclerosis. Nat Genet. 1996;13(4):472-476. (Pubitemid 26256624)
14. Teitelbaum D, Webb C, Bree M, Meshorer A, Arnon R, Sela M. Suppression of experimental allergic encephalomyelitis in Rhesus monkeys by a synthetic basic copolymer. Clin Immunol Immunopathol. 1974;3(2):256-262.
15. Keith AB, Arnon R, Teitelbaum D, Caspary EA, Wisniewski HM. The effect of Cop 1, a synthetic polypeptide, on chronic relapsing experimental allergic encephalomyelitis in guinea pigs. J Neurol Sci. 1979;42(2):267-274.
16. Abramsky O, Teitelbaum D, Arnon R. Effect of a synthetic polypeptide (COP 1) on patients with multiple sclerosis and with acute disseminated encephalomyelitis: preliminary report. J Neurol Sci. 1977;31(3):433-438.
17. Bornstein MB, Miller A, Slagle S, et al. A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis. N Engl J Med. 1987;317(7):408-414. (Pubitemid 17131177)
18. Johnson KP, Brooks BR, Cohen JA, et al; the Copolymer 1 Multiple Sclerosis Study Group. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. Neurology. 1995;45(7):1268-1276.
19. Ford C, Goodman AD, Johnson K, et al. Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate. Mult Scler. 2010;16(3):342-350.
20. Comi G, Filippi M, Wolinsky JS; European/Canadian Glatiramer Acetate Study Group. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging - measured disease activity and burden in patients with relapsing multiple sclerosis. Ann Neurol. 2001;49(3):290-297.
21. Comi G, Martinelli V, Rodegher M, et al; PreCISe Study Group. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet. 2009;374(9700):1503-1511.
22. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis, I: clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology. 1993;43(4):655-661.
23. Luster AD, Alon R, von Andrian UH. Immune cell migration in inflammation: present and future therapeutic targets. Nat Immunol. 2005;6(12):1182-1190.
24. Vajkoczy P, Laschinger M, Engelhardt B. Alpha4-integrin-VCAM-1 binding mediates G protein-independent capture of encephalitogenic T cell blasts to CNS white matter microvessels. J Clin Invest. 2001;108(4):557-565.
25. Shimizu Y, van Seventer GA, Horgan KJ, Shaw S. Costimulation of proliferative responses of resting CD4+ T cells by the interaction of VLA-4 and VLA-5 with fibronectin or VLA-6 with laminin. J Immunol. 1990;145(1):59-67. (Pubitemid 20217383)
26. Yednock TA, Cannon C, Fritz LC, Sanchez-Madrid F, Steinman L, Karin N. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature. 1992;356(6364):63-66.
27. Theien BE, Vanderlugt CL, Eagar TN, et al. Discordant effects of anti-VLA-4 treatment before and after onset of relapsing experimental autoimmune encephalomyelitis. J Clin Invest. 2001;107(8):995-1006.
28. Kanwar JR, Harrison JE, Wang D, et al. Beta7 integrins contribute to demyelinating disease of the central nervous system. J Neuroimmunol. 2000;103(2):146-152.
29. Polman CH, O'Connor PW, Havrdova E, et al; AFFIRM Investigators. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):899-910.
30. Rudick RA, Stuart WH, Calabresi PA, et al; SENTINEL Investigators. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):911-923.
31. Polman CH, Uitdehaag BM. New and emerging treatment options for multiple sclerosis. Lancet Neurol. 2003;2(9):563-566.
32. Yong VW, Chabot S, Stuve O, Williams G. Interferon beta in the treatment of multiple sclerosis: mechanisms of action. Neurology. 1998;51(3):682-689. (Pubitemid 28449243)
33. Dhib-Jalbut S, Marks S. Interferon-beta mechanisms of action in multiple sclerosis. Neurology. 2010;74(suppl 1):S17-S24.
34. Weber MS, Hohlfeld R, Zamvil SS. Mechanism of action of glatiramer acetate in treatment of multiple sclerosis. Neurotherapeutics. 2007;4(4):647-653.
35. Racke MK, Lovett-Racke AE, Karandikar NJ. The mechanism of action of glatiramer acetate treatment in multiple sclerosis. Neurology. 2010;74(suppl 1):S25-S30.
36. Stüve O, Greenberg BM. Anticipated benefits and surprising effects of daclizumab in multiple sclerosis. Lancet Neurol. 2010;9(4):337-338.
37. Bielekova B, Catalfamo M, Reichert-Scrivner S, et al. Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci U S A. 2006;103(15):5941-5946.
38. Berger JR, Houff S. Progressive multifocal leukoencephalopathy: lessons from AIDS and natalizumab. Neurol Res. 2006;28(3):299-305.
39. Clifford DB, De Luca A, DeLuca A, et al. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases [published correction appears in Lancet Neurol. 2010;9(5):463]. Lancet Neurol. 2010;9(4):438-446.
40. Hartung HP. New cases of progressive multifocal leukoencephalopathy after treatment with natalizumab. Lancet Neurol. 2009;8(1):28-31.
41. Stüve O, Marra CM, Jerome KR, et al. Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol. 2006;59(5):743-747. (Pubitemid 43673151)
42. Stüve O, Marra CM, Bar-Or A, et al. Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis. Arch Neurol. 2006;63(10):1383-1387.
43. Niino M, Bodner C, Simard ML, et al. Natalizumab effects on immune cell responses in multiple sclerosis. Ann Neurol. 2006;59(5):748-754.
44. del Pilar Martin M, Cravens PD, Winger R, et al. Decrease in the numbers of dendritic cells and CD4+ T cells in cerebral perivascular spaces due to natalizumab. Arch Neurol. 2008;65(12):1596-1603.
45. Zohren F, Toutzaris D, Klarner V, Hartung HP, Kieseier B, Haas R. The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans. Blood. 2008;111(7):3893-3895.
46. Cotte S, von Ahsen N, Kruse N, et al. ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis. Brain. 2009;132(pt 9):2517-2530.
47. Dutta R, Trapp BD. Pathogenesis of axonal and neuronal damage in multiple sclerosis. Neurology. 2007;68(22)(suppl 3):S22-S31. (Pubitemid 46848608)
48. Truyen L, van Waesberghe JH, van Walderveen MA, et al. Accumulation of hypointense lesions ("black holes") on T1 spin-echo MRI correlates with disease progression in multiple sclerosis. Neurology. 1996;47(6):1469-1476.
49. Filippi M, Rovaris M, Rocca MA, Sormani MP, Wolinsky JS, Comi G; European/Canadian Glatiramer Acetate Study Group. Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes." Neurology. 2001;57(4):731-733.
50. Dalton CM, Miszkiel KA, Barker GJ, et al. Effect of natalizumab on conversion of gadolinium enhancing lesions to T1 hypointense lesions in relapsing multiple sclerosis. J Neurol. 2004;251(4):407-413.
51. Barkhof F, Hulst HE, Drulovic J, Uitdehaag BM, Matsuda K, Landin R; MN166-001 Investigators. Ibudilast in relapsing-remitting multiple sclerosis: a neuroprotectant? Neurology. 2010;74(13):1033-1040.
52. Bermel RA, Bakshi R. The measurement and clinical relevance of brain atrophy in multiple sclerosis. Lancet Neurol. 2006;5(2):158-170. (Pubitemid 43107851)
53. Simon JH. Brain atrophy in multiple sclerosis: what we know and would like to know. Mult Scler. 2006;12(6):679-687.
54. Fisniku LK, Chard DT, Jackson JS, et al. Gray matter atrophy is related to long-term disability in multiple sclerosis. Ann Neurol. 2008;64(3):247-254.
55. Simon B, Schmidt S, Lukas C, et al. Improved in vivo detection of cortical lesions in multiple sclerosis using double inversion recovery MR imaging at 3 Tesla [published online January 22, 2010]. Eur Radiol. doi:10.1007/s00330-009-1705-y.
56. Calabrese M, Rocca MA, Atzori M, et al. A 3-year magnetic resonance imaging study of cortical lesions in relapse-onset multiple sclerosis. Ann Neurol. 2010;67(3):376-383.
57. Narayana PA. Magnetic resonance spectroscopy in the monitoring of multiple sclerosis. J Neuroimaging. 2005;15(4)(suppl):46S-57S.
58. Khan O, Shen Y, Caon C, et al. Axonal metabolic recovery and potential neuroprotective effect of glatiramer acetate in relapsing-remitting multiple sclerosis. Mult Scler. 2005;11(6):646-651.
59. Wolff SD, Balaban RS. Magnetization transfer imaging: practical aspects and clinical applications. Radiology. 1994;192(3):593-599.
60. Schmierer K, Scaravilli F, Altmann DR, Barker GJ, Miller DH. Magnetization transfer ratio and myelin in postmortem multiple sclerosis brain. Ann Neurol. 2004;56(3):407-415. (Pubitemid 39166560)
61. Agosta F, Rovaris M, Pagani E, Sormani MP, Comi G, Filippi M. Magnetization transfer MRI metrics predict the accumulation of disability 8 years later in patients with multiple sclerosis. Brain. 2006;129(pt 10):2620-2627.
62. Bammer R, Augustin M, Strasser-Fuchs S, et al. Magnetic resonance diffusion tensor imaging for characterizing diffuse and focal white matter abnormalities in multiple sclerosis. Magn Reson Med. 2000;44(4):583-591.
63. Benedict RH, Bruce J, Dwyer MG, et al. Diffusion-weighted imaging predicts cognitive impairment in multiple sclerosis. Mult Scler. 2007;13(6):722-730.
64. Dexter DT, Carayon A, Javoy-Agid F, et al. Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain. 1991;114(pt 4):1953-1975.
65. Stankiewicz J, Panter SS, Neema M, Arora A, Batt CE, Bakshi R. Iron in chronic brain disorders: imaging and neurotherapeutic implications. Neurotherapeutics. 2007;4(3):371-386. (Pubitemid 46962416)
66. Connor JR, Snyder BS, Arosio P, Loeffler DA, LeWitt P. A quantitative analysis of isoferritins in select regions of aged, parkinsonian, and Alzheimer's diseased brains. J Neurochem. 1995;65(2):717-724.
67. Hammond KE, Metcalf M, Carvajal L, et al. Quantitative in vivo magnetic resonance imaging of multiple sclerosis at 7 Tesla with sensitivity to iron. Ann Neurol. 2008;64(6):707-713.
68. Haacke EM, Makki M, Ge Y, et al. Characterizing iron deposition in multiple sclerosis lesions using susceptibility weighted imaging. J Magn Reson Imaging. 2009;29(3):537-544.
69. Bakshi R, Thompson AJ, Rocca MA, et al. MRI in multiple sclerosis: current status and future prospects. Lancet Neurol. 2008;7(7):615-625.
70. Frohman EM, Frohman TC, Zee DS, McColl R, Galetta S. The neuroophthalmology of multiple sclerosis. Lancet Neurol. 2005;4(2):111-121.
71. Quigley HA, Addicks EM. Quantitative studies of retinal nerve fiber layer defects. Arch Ophthalmol. 1982;100(5):807-814.
72. Hayreh SS, Massanari RM, Yamada T, Hayreh SM. Experimental allergic encephalomyelitis, I: optic nerve and central nervous system manifestations. Invest Ophthalmol Vis Sci. 1981;21(2):256-269.
73. Guy J, Ellis EA, Kelley K, Hope GM, Rao NA. Quantitative analysis of labelled inner retinal proteins in experimental optic neuritis. Curr Eye Res. 1989;8(3):253-260.
74. Guy J, Ellis EA, Tark EF III, Hope GM, Rao NA. Axonal transport reductions in acute experimental allergic encephalomyelitis: qualitative analysis of the optic nerve. Curr Eye Res. 1989;8(3):261-269.
75. Maehlen J, Olsson T, Zachau A, Klareskog L, Kristensson K. Local enhancement of major histocompatibility complex (MHC) class I and II expression and cell infiltration in experimental allergic encephalomyelitis around axotomized motor neurons. J Neuroimmunol. 1989;23(2):125-132. (Pubitemid 19144793)
76. White SR, Samathanam GK, Bowker RM, Wessendorf MW. Damage to bulbospinal serotonin-, tyrosine hydroxylase-, and TRH-containing axons occurs early in the development of experimental allergic encephalomyelitis in rats. J Neurosci Res. 1990;27(1):89-98.
77. Zhu B, Moore GR, Zwimpfer TJ, et al. Axonal cytoskeleton changes in experimental optic neuritis. Brain Res. 1999;824(2):204-217.
78. Mancardi G, Hart BA, Capello E, et al. Restricted immune responses lead to CNS demyelination and axonal damage. J Neuroimmunol. 2000;107(2):178-183.
79. Kornek B, Storch MK, Weissert R, et al. Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. Am J Pathol. 2000;157(1):267-276.
80. Mancardi G, Hart B, Roccatagliata L, et al. Demyelination and axonal damage in a non-human primate model of multiple sclerosis. J Neurol Sci. 2001;184(1):41-49.
81. Wujek JR, Bjartmar C, Richer E, et al. Axon loss in the spinal cord determines permanent neurological disability in an animal model of multiple sclerosis. J Neuropathol Exp Neurol. 2002;61(1):23-32.
82. Craner MJ, Lo AC, Black JA, Waxman SG. Abnormal sodium channel distribution in optic nerve axons in a model of inflammatory demyelination. Brain. 2003;126(pt 7):1552-1561.
83. Craner MJ, Hains BC, Lo AC, Black JA, Waxman SG. Co-localization of sodium channel Nav1.6 and the sodium-calcium exchanger at sites of axonal injury in the spinal cord in EAE. Brain. 2004;127(pt 2):294-303.
84. Hobom M, Storch MK, Weissert R, et al. Mechanisms and time course of neuronal degeneration in experimental autoimmune encephalomyelitis. Brain Pathol. 2004;14(2):148-157. (Pubitemid 38656386)
85. Wang D, Ayers MM, Catmull DV, Hazelwood LJ, Bernard CC, Orian JM. Astrocyte-associated axonal damage in pre-onset stages of experimental autoimmune encephalomyelitis. Glia. 2005;51(3):235-240. (Pubitemid 41297430)
86. Kim JH, Budde MD, Liang HF, et al. Detecting axon damage in spinal cord from a mouse model of multiple sclerosis. Neurobiol Dis. 2006;21(3):626-632.
87. Fukuchi T, Takahashi K, Shou K, Matsumura M. Optical coherence tomography (OCT) findings in normal retina and laser-induced choroidal neovascularization in rats. Graefes Arch Clin Exp Ophthalmol. 2001;239(1):41-46.
88. Sho K, Takahashi K, Fukuchi T, Matsumura M. Quantitative evaluation of ischemia-reperfusion injury by optical coherence tomography in the rat retina. Jpn J Ophthalmol. 2005;49(2):109-113.
89. Li Q, Timmers AM, Hunter K, et al. Noninvasive imaging by optical coherence tomography to monitor retinal degeneration in the mouse. Invest Ophthalmol Vis Sci. 2001;42(12):2981-2989.
90. Horio N, Kachi S, Hori K, et al. Progressive change of optical coherence tomography scans in retinal degeneration slow mice. Arch Ophthalmol. 2001;119(9):1329-1332. (Pubitemid 32994878)
91. Grieve K, Paques M, Dubois A, Sahel J, Boccara C, Le Gargasson JF. Ocular tissue imaging using ultrahigh-resolution, full-field optical coherence tomography. Invest Ophthalmol Vis Sci. 2004;45(11):4126-4131. (Pubitemid 39411170)
92. Parisi V, Manni G, Spadaro M, et al. Correlation between morphological and functional retinal impairment in multiple sclerosis patients. Invest Ophthalmol Vis Sci. 1999;40(11):2520-2527. (Pubitemid 29455479)
93. Trip SA, Schlottmann PG, Jones SJ, et al. Optic nerve atrophy and retinal nerve fibre layer thinning following optic neuritis: evidence that axonal loss is a substrate of MRI-detected atrophy. Neuroimage. 2006;31(1):286-293.
94. Costello F, Coupland S, Hodge W, et al. Quantifying axonal loss after optic neuritis with optical coherence tomography. Ann Neurol. 2006;59(6):963-969. (Pubitemid 43830928)
95. Balcer LJ, Galetta SL, Calabresi PA, et al. Natalizumab reduces visual loss in patients with relapsing multiple sclerosis. Neurology. 2007;68(16):1299-1304. (Pubitemid 46625976)
96. Pozzessere G, Valle E, Rossi P, et al. Pupillometric evaluation and analysis of light reflex in healthy subjects as a tool to study autonomic nervous system changes with aging. Aging (Milano). 1996;8(1):55-60.
97. Bitsios P, Prettyman R, Szabadi E. Changes in autonomic function with age: a study of pupillary kinetics in healthy young and old people. Age Ageing. 1996;25(6):432-438.
98. Prettyman R, Bitsios P, Szabadi E. Altered pupillary size and darkness and light reflexes in Alzheimer's disease. J Neurol Neurosurg Psychiatry. 1997;62(6):665-668.
99. O'Neill WD, Oroujeh AM, Keegan AP, Merritt SL. Neurological pupillary noise in narcolepsy. J Sleep Res. 1996;5(4):265-271.
100. O'Neill WD, Oroujeh AM, Merritt SL. Pupil noise is a discriminator between narcoleptics and controls. IEEE Trans Biomed Eng. 1998;45(3):314-322.
101. Bitsios P, Szabadi E, Bradshaw CM. Comparison of the effects of venlafaxine, paroxetine and desipramine on the pupillary light reflex in man. Psychopharmacology (Berl). 1999;143(3):286-292. (Pubitemid 29204983)
102. Brown SM, Khanani AM, McCartney DL. The effect of daily use of brimonidine tartrate on the dark-adapted pupil diameter. Am J Ophthalmol. 2004;138(1):149-151. (Pubitemid 38850268)
103. Knaggs RD, Crighton IM, Cobby TF, Fletcher AJ, Hobbs GJ. The pupillary effects of intravenous morphine, codeine, and tramadol in volunteers. Anesth Analg. 2004;99(1):108-112.
104. Wilhelm B, Giedke H, Ludtke H, Bittner E, Hofmann A, Wilhelm H. Daytime variations in central nervous system activation measured by a pupillographic sleepiness test. J Sleep Res. 2001;10(1):1-7.
105. McLaren JW, Hauri PJ, Lin SC, Harris CD. Pupillometry in clinically sleepy patients. Sleep Med. 2002;3(4):347-352.
106. Merritt SL, Schnyders HC, Patel M, Basner RC, O'Neill W. Pupil staging and EEG measurement of sleepiness. Int J Psychophysiol. 2004;52(1):97-112.
107. Morad Y, Lemberg H, Yofe N, Dagan Y. Pupillography as an objective indicator of fatigue. Curr Eye Res. 2000;21(1):535-542.
108. Barvais L, Engelman E, Eba JM, Coussaert E, Cantraine F, Kenny GN. Effect site concentrations of remifentanil and pupil response to noxious stimulation. Br J Anaesth. 2003;91(3):347-352. (Pubitemid 37063349)
109. Donaldson GW, Chapman CR, Nakamura Y, Bradshaw DH, Jacobson RC, Chapman CN. Pain and the defense response: structural equation modeling reveals a coordinated psychophysiological response to increasing painful stimulation. Pain. 2003;102(1-2):97-108.
110. Tegeder I, Meier S, Burian M, Schmidt H, Geisslinger G, Lotsch J. Peripheral opioid analgesia in experimental human pain models. Brain. 2003;126(pt 5):1092-1102.
111. Hussain RZ, Hopkins SC, Frohman EM, et al. Direct and consensual murine pupillary reflex metrics: establishing normative values. Auton Neurosci. 2009;151(2):164-167.
112. Waxman SG. Ion channels and neuronal dysfunction in multiple sclerosis. Arch Neurol. 2002;59(9):1377-1380.
113. Armstrong RJ, Barker RA. Neurodegeneration: a failure of neuroregeneration? Lancet. 2001;358(9288):1174-1176.
114. Zivadinov R. Can imaging techniques measure neuroprotection and remyelination in multiple sclerosis? Neurology. 2007;68(22)(suppl 3):S72-S82. (Pubitemid 46848615)
115. Comi G, Filippi M. Clinical trials in multiple sclerosis: methodological issues. Curr Opin Neurol. 2005;18(3):245-252. (Pubitemid 40813750)
116. Bechtold DA, Miller SJ, Dawson AC, et al. Axonal protection achieved in a model of multiple sclerosis using lamotrigine. J Neurol. 2006;253(12):1542- 1551. (Pubitemid 46115434)
117. Pitt D, Werner P, Raine CS. Glutamate excitotoxicity in a model of multiple sclerosis. Nat Med. 2000;6(1):67-70.
118. Gilgun-Sherki Y, Panet H, Melamed E, Offen D. Riluzole suppresses experimental autoimmune encephalomyelitis: implications for the treatment of multiple sclerosis. Brain Res. 2003;989(2):196-204.
119. Kalkers NF, Barkhof F, Bergers E, van Schijndel R, Polman CH. The effect of the neuroprotective agent riluzole on MRI parameters in primary progressive multiple sclerosis: a pilot study. Mult Scler. 2002;8(6):532-533.
120. Kapoor R, Davies M, Blaker PA, Hall SM, Smith KJ. Blockers of sodium and calcium entry protect axons from nitric oxide-mediated degeneration. Ann Neurol. 2003;53(2):174-180.
121. Pryce G, Ahmed Z, Hankey DJ, et al. Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. Brain. 2003;126(pt 10):2191-2202. (Pubitemid 37432364)
122. Centonze D, Bari M, Rossi S, et al. The endocannabinoid system is dysregulated in multiple sclerosis and in experimental autoimmune encephalomyelitis. Brain. 2007;130(pt 10):2543-2553.
123. Ullrich O, Merker K, Timm J, Tauber S. Immune control by endocannabinoids - new mechanisms of neuroprotection? J Neuroimmunol. 2007;184(1-2):127-135.
124. Black JA, Liu S, Hains BC, Saab CY, Waxman SG. Long-term protection of central axons with phenytoin in monophasic and chronic-relapsing EAE. Brain. 2006;129(pt 12):3196-3208. (Pubitemid 44871436)
125. Smith KJ. Sodium channels and multiple sclerosis: roles in symptom production, damage and therapy. Brain Pathol. 2007;17(2):230-242.
126. Aktas O, Prozorovski T, Smorodchenko A, et al. Green tea epigallocatechin-3-gallate mediates T cellular NF-kappa B inhibition and exerts neuroprotection in autoimmune encephalomyelitis. J Immunol. 2004;173(9):5794- 5800. (Pubitemid 39392169)
127. Killestein J, Kalkers NF, Polman CH. Glutamate inhibition in MS: the neuroprotective properties of riluzole. J Neurol Sci. 2005;233(1-2):113-115.
128. Vaney C, Heinzel-Gutenbrunner M, Jobin P, et al. Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study. Mult Scler. 2004;10(4):417-424.
129. Rudick RA, Cohen JA, Weinstock-Guttman B, Kinkel RP, Ransohoff RM. Management of multiple sclerosis. N Engl J Med. 1997;337(22):1604-1611.
130. Piaton G, Williams A, Seilhean D, Lubetzki C. Remyelination in multiple sclerosis. Prog Brain Res. 2009;175:453-464.
131. Franklin RJ, Ffrench-Constant C. Remyelination in the CNS: from biology to therapy. Nat Rev Neurosci. 2008;9(11):839-855.
132. Watzlawik J, Warrington AE, Rodriguez M. Importance of oligodendrocyte protection, BBB breakdown and inflammation for remyelination. Expert Rev Neurother. 2010;10(3):441-457.
133. Racke MK, Dhib-Jalbut S, Cannella B, Albert PS, Raine CS, McFarlin DE. Prevention and treatment of chronic relapsing experimental allergic encephalomyelitis by transforming growth factor-beta 1. J Immunol. 1991;146(9):3012-3017.
134. Rodriguez M. Effectors of demyelination and remyelination in the CNS: implications for multiple sclerosis. Brain Pathol. 2007;17(2):219-229.
135. Calabresi PA, Fields NS, Maloni HW, et al. Phase 1 trial of transforming growth factor beta 2 in chronic progressive MS. Neurology. 1998;51(1):289-292. (Pubitemid 28345406)